These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

174 related articles for article (PubMed ID: 12736113)

  • 41. Durvalumab, with or without tremelimumab, plus platinum-etoposide versus platinum-etoposide alone in first-line treatment of extensive-stage small-cell lung cancer (CASPIAN): updated results from a randomised, controlled, open-label, phase 3 trial.
    Goldman JW; Dvorkin M; Chen Y; Reinmuth N; Hotta K; Trukhin D; Statsenko G; Hochmair MJ; Özgüroğlu M; Ji JH; Garassino MC; Voitko O; Poltoratskiy A; Ponce S; Verderame F; Havel L; Bondarenko I; Każarnowicz A; Losonczy G; Conev NV; Armstrong J; Byrne N; Thiyagarajah P; Jiang H; Paz-Ares L;
    Lancet Oncol; 2021 Jan; 22(1):51-65. PubMed ID: 33285097
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Comparison of conventional dose and double dose carboplatin in patients receiving cyclophosphamide plus carboplatin for advanced ovarian carcinoma: a North Central Cancer Treatment Group Study.
    Edmonson JH; Suman VJ; Dalton RJ; Bro WC; Gallenberg MM; Long HJ; Levitt R; Hatfield AK; Krook JE; Mailliard JA; Gerstner JB;
    Cancer Invest; 2001; 19(6):597-602. PubMed ID: 11486702
    [TBL] [Abstract][Full Text] [Related]  

  • 43. ICON2: randomised trial of single-agent carboplatin against three-drug combination of CAP (cyclophosphamide, doxorubicin, and cisplatin) in women with ovarian cancer. ICON Collaborators. International Collaborative Ovarian Neoplasm Study.
    Lancet; 1998 Nov; 352(9140):1571-6. PubMed ID: 9843101
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Phase III trial of high-dose sequential chemotherapy with peripheral blood stem cell support compared with standard dose chemotherapy for first-line treatment of advanced ovarian cancer: intergroup trial of the AGO-Ovar/AIO and EBMT.
    Möbus V; Wandt H; Frickhofen N; Bengala C; Champion K; Kimmig R; Ostermann H; Hinke A; Ledermann JA; ;
    J Clin Oncol; 2007 Sep; 25(27):4187-93. PubMed ID: 17698804
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Feasibility study comparing docetaxel-cisplatin versus docetaxel-carboplatin as first-line chemotherapy for ovarian cancer.
    Minagawa Y; Kigawa J; Kanamori Y; Itamochi H; Terakawa N; Okada M; Kitada F
    Gynecol Oncol; 2006 Jun; 101(3):495-8. PubMed ID: 16375950
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Five year follow-up and dose delivery analysis of cisplatin, iproplatin or carboplatin in combination with cyclophosphamide in advanced ovarian carcinoma.
    Gurney H; Crowther D; Anderson H; Murphy D; Prendiville J; Ranson M; Mayor P; Swindell R; Buckley CH; Tindall VR
    Ann Oncol; 1990 Nov; 1(6):427-33. PubMed ID: 2083186
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Phase I trial of carboplatin, paclitaxel, etoposide, and cyclophosphamide with granulocyte colony stimulating factor as first-line therapy for patients with advanced epithelial ovarian cancer.
    Tung N; Berkowitz R; Matulonis U; Quartulli M; Seiden M; Kim Y; Niloff J; Cannistra SA
    Gynecol Oncol; 2000 May; 77(2):271-7. PubMed ID: 10785477
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Standard chemotherapy with or without bevacizumab for women with newly diagnosed ovarian cancer (ICON7): overall survival results of a phase 3 randomised trial.
    Oza AM; Cook AD; Pfisterer J; Embleton A; Ledermann JA; Pujade-Lauraine E; Kristensen G; Carey MS; Beale P; Cervantes A; Park-Simon TW; Rustin G; Joly F; Mirza MR; Plante M; Quinn M; Poveda A; Jayson GC; Stark D; Swart AM; Farrelly L; Kaplan R; Parmar MK; Perren TJ;
    Lancet Oncol; 2015 Aug; 16(8):928-36. PubMed ID: 26115797
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Randomized controlled trial of single-agent paclitaxel versus cyclophosphamide, doxorubicin, and cisplatin in patients with recurrent ovarian cancer who responded to first-line platinum-based regimens.
    Cantù MG; Buda A; Parma G; Rossi R; Floriani I; Bonazzi C; Dell'Anna T; Torri V; Colombo N
    J Clin Oncol; 2002 Mar; 20(5):1232-7. PubMed ID: 11870165
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Cyclophosphamide and cisplatin versus paclitaxel and cisplatin: a phase III randomized trial in patients with suboptimal stage III/IV ovarian cancer (from the Gynecologic Oncology Group).
    McGuire WP; Hoskins WJ; Brady MF; Kucera PR; Partridge EE; Look KY; Clarke-Pearson DL; Davidson M
    Semin Oncol; 1996 Oct; 23(5 Suppl 12):40-7. PubMed ID: 8941409
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Randomized intergroup trial of cisplatin-paclitaxel versus cisplatin-cyclophosphamide in women with advanced epithelial ovarian cancer: three-year results.
    Piccart MJ; Bertelsen K; James K; Cassidy J; Mangioni C; Simonsen E; Stuart G; Kaye S; Vergote I; Blom R; Grimshaw R; Atkinson RJ; Swenerton KD; Trope C; Nardi M; Kaern J; Tumolo S; Timmers P; Roy JA; Lhoas F; Lindvall B; Bacon M; Birt A; Andersen JE; Zee B; Paul J; Baron B; Pecorelli S
    J Natl Cancer Inst; 2000 May; 92(9):699-708. PubMed ID: 10793106
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Phase III randomized trial comparing moderate-dose cisplatin to combined cisplatin and carboplatin in addition to mitomycin and ifosfamide in patients with stage IV non-small-cell lung cancer.
    Sculier JP; Lafitte JJ; Paesmans M; Thiriaux J; Alexopoulos CG; Baumöhl J; Schmerber J; Koumakis G; Florin MC; Zacharias C; Berghmans T; Mommen P; Ninane V; Klastersky J
    Br J Cancer; 2000 Nov; 83(9):1128-35. PubMed ID: 11027424
    [TBL] [Abstract][Full Text] [Related]  

  • 53. The impact of received dose intensity on the outcome of advanced ovarian cancer.
    Repetto L; Pace M; Mammoliti S; Bruzzone M; Chiara S; Oliva C; Guido T; Conte PF; Campora E; Rubagotti A
    Eur J Cancer; 1993; 29A(2):181-4. PubMed ID: 8422279
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Comparing Paclitaxel-Carboplatin with Paclitaxel-Cisplatin as the Front-Line Chemotherapy for Patients with FIGO IIIC Serous-Type Tubo-Ovarian Cancer.
    Huang CY; Cheng M; Lee NR; Huang HY; Lee WL; Chang WH; Wang PH
    Int J Environ Res Public Health; 2020 Mar; 17(7):. PubMed ID: 32224896
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Cisplatin combined with carboplatin: a new way of intensification of platinum dose in the treatment of advanced ovarian cancer. Belgian Study Group for Ovarian Carcinoma.
    Piccart MJ; Nogaret JM; Marcelis L; Longrée H; Ries F; Kains JP; Gobert P; Domange AM; Sculier JP; Gompel C
    J Natl Cancer Inst; 1990 Apr; 82(8):703-7. PubMed ID: 2181152
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Intraperitoneal versus intravenous cisplatin in combination with intravenous cyclophosphamide and epidoxorubicin in optimally cytoreduced advanced epithelial ovarian cancer: a randomized trial of the Gruppo Oncologico Nord-Ovest.
    Gadducci A; Carnino F; Chiara S; Brunetti I; Tanganelli L; Romanini A; Bruzzone M; Conte PF
    Gynecol Oncol; 2000 Feb; 76(2):157-62. PubMed ID: 10637064
    [TBL] [Abstract][Full Text] [Related]  

  • 57. A randomised trial investigating the dose intensity of primary chemotherapy in patients with ovarian carcinoma: a comparison of chemotherapy given every four weeks with the same chemotherapy given at three week intervals.
    Wrigley E; Weaver A; Jayson G; Ranson M; Renninson J; Prendiville J; Dobson M; Collins CD; Swindell R; Buckley CH; Radford JA; Crowther D
    Ann Oncol; 1996 Sep; 7(7):705-11. PubMed ID: 8905028
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Analysis of patient age as an independent prognostic factor for survival in a phase III study of cisplatin-cyclophosphamide versus carboplatin-cyclophosphamide in stages III (suboptimal) and IV ovarian cancer. A Southwest Oncology Group study.
    Alberts DS; Dahlberg S; Green SJ; Garcia D; Hannigan EV; O'Toole R; Stock-Novack D; Surwit EA; Malviya VK; Jolles CJ
    Cancer; 1993 Jan; 71(2 Suppl):618-27. PubMed ID: 8420685
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Continuous Low-Dose Oral Cyclophosphamide and Methotrexate as Maintenance Therapy in Patients With Advanced Ovarian Carcinoma After Complete Clinical Response to Platinum and Paclitaxel Chemotherapy.
    El-Husseiny K; Motawei H; Ali MS
    Int J Gynecol Cancer; 2016 Mar; 26(3):437-42. PubMed ID: 26825824
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Randomized trial of initial therapy with melphalan versus cisplatin-based combination chemotherapy in patients with advanced ovarian carcinoma: initial and long term results--Eastern Cooperative Oncology Group Study E2878.
    Wadler S; Yeap B; Vogl S; Carbone P
    Cancer; 1996 Feb; 77(4):733-42. PubMed ID: 8616766
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.